Technical Analysis for VOR - Vor Biopharma Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.92 | -0.52% | -0.01 |
VOR closed down 0.52 percent on Monday, March 18, 2024, on 1.9 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 21
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Outside Day | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | -0.52% | |
Inside Day | Range Contraction | -0.52% | |
Gapped Up | Strength | -0.52% | |
Oversold Stochastic | Weakness | -0.52% | |
Stochastic Reached Oversold | Weakness | 4.07% | |
Lower Bollinger Band Touch | Weakness | 4.07% | |
Oversold Stochastic | Weakness | 4.07% | |
MACD Bearish Signal Line Cross | Bearish | -4.48% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 16 hours ago |
Up 3% | about 16 hours ago |
Up 2% | about 16 hours ago |
60 Minute Opening Range Breakdown | about 22 hours ago |
1.5x Volume Pace | about 22 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Acute Myeloid Leukemia Tyrosine Kinase Receptors Proteins Therapies For Cancer Haematopoiesis Lintuzumab
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Acute Myeloid Leukemia Tyrosine Kinase Receptors Proteins Therapies For Cancer Haematopoiesis Lintuzumab
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.175 |
52 Week Low | 1.62 |
Average Volume | 278,100 |
200-Day Moving Average | 2.57 |
50-Day Moving Average | 2.23 |
20-Day Moving Average | 2.08 |
10-Day Moving Average | 2.07 |
Average True Range | 0.17 |
RSI (14) | 41.18 |
ADX | 14.92 |
+DI | 18.47 |
-DI | 27.65 |
Chandelier Exit (Long, 3 ATRs) | 1.91 |
Chandelier Exit (Short, 3 ATRs) | 2.29 |
Upper Bollinger Bands | 2.37 |
Lower Bollinger Band | 1.80 |
Percent B (%b) | 0.21 |
BandWidth | 27.44 |
MACD Line | -0.07 |
MACD Signal Line | -0.04 |
MACD Histogram | -0.0251 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.15 | ||||
Resistance 3 (R3) | 2.15 | 2.07 | 2.11 | ||
Resistance 2 (R2) | 2.07 | 2.02 | 2.07 | 2.09 | |
Resistance 1 (R1) | 2.00 | 1.98 | 1.96 | 2.00 | 2.08 |
Pivot Point | 1.92 | 1.92 | 1.91 | 1.92 | 1.92 |
Support 1 (S1) | 1.85 | 1.87 | 1.81 | 1.85 | 1.76 |
Support 2 (S2) | 1.77 | 1.83 | 1.77 | 1.75 | |
Support 3 (S3) | 1.70 | 1.77 | 1.73 | ||
Support 4 (S4) | 1.70 |